Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Jazz Pharmaceuticals plc

J7Z
Current price
114.95 EUR -0.05 EUR (-0.04%)
Last closed 116.50 EUR
ISIN IE00B4Q5ZN47
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 7 348 558 576 EUR
Yield for 12 month +4.83 %
1Y
3Y
5Y
10Y
15Y
J7Z
21.11.2021 - 28.11.2021

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, D04 E5W7

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

203.34 EUR

P/E ratio

17.60

Dividend Yield

Current Year

+3 739 288 280 EUR

Last Year

+3 568 786 197 EUR

Current Quarter

+1 028 853 242 EUR

Last Quarter

+998 480 212 EUR

Current Year

+3 314 493 989 EUR

Last Year

+3 041 649 695 EUR

Current Quarter

+920 005 173 EUR

Last Quarter

+891 298 836 EUR

Key Figures J7Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 555 658 065 EUR
Operating Margin TTM 24.67 %
PE Ratio 17.60
Return On Assets TTM 4.62 %
PEG Ratio 0.84
Return On Equity TTM 12.09 %
Wall Street Target Price 203.34 EUR
Revenue TTM 4 090 468 447 EUR
Book Value 70.70 EUR
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 8.50 %
Dividend Yield
Gross Profit TTM 3 475 303 934 EUR
Earnings per share 6.91 EUR
Diluted Eps TTM 6.91 EUR
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY 59.70 %
Profit Margin 11.60 %

Dividend Analytics J7Z

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History J7Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation J7Z

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 17.60
Forward PE 6.11
Enterprise Value Revenue 2.76
Price Sales TTM 1.80
Enterprise Value EBITDA 8.44
Price Book MRQ 1.78

Financials J7Z

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators J7Z

For 52 weeks

94.66 EUR 125.91 EUR
50 Day MA 112.19 EUR
Shares Short Prior Month
200 Day MA 106.13 EUR
Short Ratio
Shares Short
Short Percent